Short stature may be an important cause of physical and psychological disadvantage. Linear growth results from a complex process of integrated physiological mechanisms and may be disturbed by a number ofthese factors acting either independently or together. As a result, a broad range of causes need to be considered in any child with subnormal growth. Table 1 shows the principal causes of short stature.
Growth disorders can be broadly categorised into two groups: those associated with normal height velocity -for example, genetic short stature, and those with subnormal height velocity -for example, growth hormone insufficiency, Turner's syndrome, and chronic illness such as coeliac disease. In children where growth is abnormally slow the degree of height deficit is related to the age of diagnosis. It is therefore in the direct interest of the child with growth hormone insufficiency to be diagnosed and treated early, enabling a better chance of achieving normal height during childhood and in adult life. Some of the conditions discussed in this article may therefore be missed unless an effective height surveillance screening programme is in operation.
Growth hormone insufficiency
As a result of a screening study of 48 221 9 year old children in Edinburgh in 1977, the prevalence of growth hormone insufficiency has been estimated at 1 per 4018. 1 Of the 13 such children identified, only four (31 %) had been diagnosed before the study. A larger study in Utah in 1994 screened 123 948 children, aged 4-10, after extensive training of non-medical staff in measurement technique with a stadiometer (79495 completed the follow Up).2 Of these children, 555 (0'7%) were identified as having a growth problem defined as a height equal to or below the third centile and growth less than 5 ern/year, Table 2 shows the identified causes.
The Utah study identified 16 children with growth hormone insufficiency, and in addition 17 had been diagnosed before the study. Consequently a total of 33 children had growth hormone insufficiency, resulting in a prevalence of 1:3480. Boys outnumbered girls by 3: 1. The overall prevalence of growth hormone insufficiency may have been even higher as some children were lost to follow up and new onset disease would have been missed.
Of 4054 children with growth hormone insufficiency enrolled into the Kabi international growth study by 1993, 3248 (80%) had isolated idiopathic growth hormone insufficiency.' The mean height standard deviation (SD) at the start of growth hormone treatment was -2'6, and the median age was 10·4 years.
Herber found that the age of diagnosis of children with isolated idiopathic growth hormone insufficiency was often late -around the age of 10 -with a height of -3,73 SDs at the start of growth hormone treatment." Earlier replacement therapy has been reported to lead to a better prognosis for final adult height. 5 A retrospective review of 2331 children receiving growth hormone therapy between 1985 and 1987 in the USA found that boys outnumbered girls significantly. 6 Of those surveyed, 19% had idiopathic short stature without growth hormone insufficiency. Idiopathic growth hormone insufficiency accounted for 59% with a mean height SD for the boys of -3,3 and for the girls -3,9. The age of onset of treatment had a bimodal distribution with peaks at ages 5 and 12.
In summary, the prevalence of growth hormone insufficiency is approximately 1:4000 and, if idiopathic, is currently treated at a mean starting age of about 10. At that age, height is usually less than 2·5 SDs below the mean. Turner's syndrome Turner's syndrome has an incidence of 1:2500 of female births." Short stature is the commonest somatic abnormality and untreated leads to a final adult height of approximately 142 ern." 9 Figure 1 shows the degree of growth failure at different ages. !Q--!2
Cause
Age (years) 2 3 4 5 6 7 8 In summary, patients with Turner's syndrome have significantly short stature with a mean height in the early school age group of more than 2 SDs below the mean. The value of human growth hormone therapy on adult height in Turner's syndrome is still being assessed, but there are reports that show a significant improvement in adult height if treatment is given to prepubertal girls with Turner's syndrome. 14 Many patients with Turner's syndrome do not have striking dysmorphic features, therefore height surveillance is an effective way of identifying this condition.
The pattern of growth in girls with untreated Turner's syndrome has been studied by a number of groups. Bernasconi found that under the age of 5, patients with Turner's syndrome had a mean height of 2 SDs below the mean." Subsequently, the difference between girls with Turner's syndrome and normal girls increases progressively reaching a maximum of -4,2 SDs at age 15. Noonan's syndrome Noonan's syndrome is an additional dysmorphic syndrome commonly associated with short stature. The incidence of Noonan's syndrome is uncertain but may be as high as 1 per 1000. 15 16 In a review of 144 patients with Noonan's syndrome 50% had heights below the third centile." Mean height in children followed along the third centile until the age of 12 (male) and 10 (female) and then fell below the normal range. Figure 2 shows the degree of short stature in a review of 151 patients with Noonan's syndrome with a mean age of 12'6. 18 The mean bone age delay was 2·0 years. Regarding weight, about 23 % were on or below the third centile. Head circumference was also affected to a lesser degree. One study found 83% of 81 patients with Noonan's syndrome had short stature. 19 Therapeutic trials ofhuman growth hormone therapy are currently in progress in patients with Noonan's syndrome, with a reported short term increase in height SDs. 20 Ifhuman growth hormone is shown to be of long term benefit, early diagnosis and onset of treatment are likely to contribute to this.
Intrauterine growth retardation Short stature occurs more commonly in patients with intrauterine growth retardation than in those appropriately grown for gestational age. Of 81 very low birth weight expremature infants, those who were small for gestational age were significantly shorter at ages 2 and 3 than those appropriately grown of the same gestational age." Table 3 summarises follow up growth studies in infants with intrauterine growth retardation. [22] [23] [24] [25] [26] [27] [28] The nature of the intrauterine growth retardation affects the incidence of short stature. Children with an adequate ponderal index (weight/length" x 100)that is, symmetrical or non-wasted intrauterine growth retardation, had lower lengths up to age 3 than those with a low ponderal index. A low ponderal index suggests late fetal growth failure and is a predictor of better catch-up growth. 29 One third of intrauterine growth retarded infants, therefore, have a high risk of short stature in childhood. Any strategy aimed at growth promotion in these patients will be helped by investigation of those with short stature as early as possible in childhood. Trials of human growth hormone are in progress. It appears that high dose therapy, perhaps on an intermittent basis, may significantly help long term growth. 30 
Coeliac disease
Short stature was quoted as a feature of childhood coeliac disease in Samuel Gee's original description of the "coeliac affection". 31 The incidence of coeliac disease is uncertain but is estimated to be 1:2000-1:6000 live births in the United Kingdom." "Failure to thrive of no apparent cause" was the mode of presentation in seven of 52 patients with coeliac disease."
Several studies have found that patients with short stature of undetermined cause, and no history of gastrointestinal disease, may have coeliac disease. Groll et at assessed 34 short patients presenting to a children's hospital with heights more than 2 SDs below the mean and no endocrine pathology and absent gastrointestinal symptoms." All underwent small bowel biopsy and seven (21 %) had total villous atrophy showing an acceleration in height velocity on a gluten free diet. In a separate study 108 short children with no gastrointestinal symptoms underwent small bowel biopsy, nine (8%) having total villous atrophy." Treatment of coeliac disease in early childhood is associated with early catch-up growth."
Most children with coeliac disease with gastrointestinal symptoms present between the ages of 1 and 5. Those presenting with short stature alone were aged 9·36 (SD 4,47) and 11·9 (3'6) years in two studies. 35 37 Coeliac disease is an example of a chronic paediatric disorder which is associated with abnormal growth and may be detected by an effective height surveillance programme. Clearly, although there is a wide spectrum of symptomatology in this disorder, the child would benefit from early diagnosis and treatment. In a study of the heights of patients with coeliac disease at the age of transfer from a paediatric to an adult clinic, the only patients with continued short stature were those who presented late in childhood."
Psychosocial growth retardation
Short stature in childhood and adolescence may be associated with psychological harassment or emotional deprivation." As early as 1947, there were reports that lack of stimulation and attention in the home or hospital could lead to disturbed growth.t'"" more commonly in boys."
The incidence of psychological short stature in the under 3 year olds is thought to be high, but as it is difficult to assess how much of the short stature is due to lack of adequate food in a poor community and how much due to parental neglect, it is not possible to obtain exact figures. Similarly, in the older age group, the frequency of the diagnosis will be proportional to the awareness of the clinician, and may be underreported. Investigations may be normal, or there may be an abnormal response to growth hormone stimulation tests, and bone age delay." Hyer, Cotterill, Savage Identifying children with this condition by an effective height surveillance prograrrtme.would enable correction of nutritional inadequacies in the younger child, which may be sufficient to correct their short stature. Identifying the "at risk" older child would enable input from a multidisciplinary team, removal from the unfavourable environment allowing them a better chance of reaching their genetic potential, protection against physical abuse, and has also been reported to improve the prognosis for intelligence."
Other conditions
Growth retardation is also a common finding in chronic renal failure. Children often have a height less than the third centile at diagnosis of their chronic renal failure." The growth failure is more pronounced the earlier renal failure occurs, and can result in marked growth retardation in infancy and puberty. Identifying these children early by height surveillance would enable intensive treatment to be given, which may allow normal growth rate," and the use of human growth hormone, which can result in a mean increment of height in prepubertal children of 0·9 SDs within two years of treatment."
Chondrodysplasia, which may not be clinically obvious as in hypochondroplasia, has an incidence of 3--4·5 per 10000 births and can result in significant growth retardation, with height SDs ranging from -7'6 to -2·2 depending on the dysplasia." Identifying these children at height surveillance would permit an early diagnosis to be made and orthopaedic opinion obtained.
Conclusion
We have discussed a number of disorders that are associated with abnormal growth and which can be identified by an effective community height surveillance programme. These conditions are commonly missed and consequently present later for paediatric review. The spectrum of these disorders from prenatal disturbance of growth to dysmorphic short stature and growth hormone insufficiency emphasises the wide range of causes of short stature. Early diagnosis and treatment are likely to contribute to beneficial management of many children with short stature.
